How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

28,942 results for

Alcoholic Hepatitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. Full Text available with Trip Pro

Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. The degree of cholestasis is an important disease driver in alcoholic hepatitis, a severe clinical condition that needs new biomarkers and targeted therapies. We aimed to identify the largely unknown mechanisms and biomarkers linked to cholestasis in alcoholic hepatitis.Herein, we analyzed a well characterized cohort of patients with alcoholic hepatitis and correlated clinical and histological parameters and outcomes with serum (...) bile acids and fibroblast growth factor 19 (FGF19), a major regulator of bile acid synthesis.We found that total and conjugated bile acids were significantly increased in patients with alcoholic hepatitis compared with controls. Serum FGF19 levels were strongly increased and gene expression of FGF19 was induced in biliary epithelial cells and ductular cells of patients with alcoholic hepatitis. De novo bile acid synthesis (CYP7A1 gene expression and C4 serum levels) was significantly decreased

2018 Journal of Hepatology

182. Aflatoxin B<sub>1</sub> exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption. Full Text available with Trip Pro

Aflatoxin B1 exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption. Hepatocarcinogenicity of aflatoxin B1 (AFB1) has rarely been studied in populations with hepatitis C virus (HCV) infection and those without hepatitis B virus (HBV) and HCV infection (non-B-non-C). This case-control study nested in a community-based cohort aimed to investigate the HCC risk associated with AFB1 in HCV-infected and non-B-non-C (...) )], but not in non-B-non-C participants without alcohol drinking habit. AFB1 exposure remained an independent risk predictor for HCV-related HCC after adjustment for other HCC predictors (multivariate-adjusted OR [95% CI], 3.65 [1.32-10.10]).AFB1 exposure contributes to the development of HCC in participants with significant risk factors for cirrhosis including alcohol and HCV infection.Copyright © 2018 Elsevier Ltd. All rights reserved.

2018 European Journal of Cancer

183. The hepatic BMAL1/AKT/Lipogenesis axis protects against alcoholic liver disease via promoting PPARα pathway. Full Text available with Trip Pro

The hepatic BMAL1/AKT/Lipogenesis axis protects against alcoholic liver disease via promoting PPARα pathway. Alcohol liver disease (ALD) is one of the major chronic liver diseases worldwide, ranging from fatty liver, alcoholic hepatitis, cirrhosis, and potentially, hepatocellular carcinoma. Epidemiological studies suggest a potential link between ALD and impaired circadian rhythms, but the role of hepatic circadian proteins in the pathogenesis of ALD remains unknown. Here we show (...) hepatic fatty acid oxidation but also alleviates ethanol-induced fatty liver and liver injury. Furthermore, hepatic over-expression of lipogenic transcription factor ChREBP, but not SREBP-1c, in the liver of Bmal1-LKO mice also increases fatty acid oxidation and partially reduces ethanol-induced fatty liver and liver injury.we identified a novel protective role of BMAL1 in hepatocytes against ALD. The protective action of BMAL1 during alcohol consumption depends on its ability to couple ChREBP-induced

2018 Hepatology

184. The prognostic value of Acute-on-Chronic Liver Failure during the course of severe alcoholic hepatitis. (Abstract)

The prognostic value of Acute-on-Chronic Liver Failure during the course of severe alcoholic hepatitis. A better identification of factors predicting death is needed in alcoholic hepatitis (AH). Acute-on-chronic liver failure (ACLF) occurs during the course of liver disease and can be identified when AH is diagnosed (prevalent ACLF [pACLF]) or during follow-up (incidental ACLF [iACLF]). This study analyzed the impact of ACLF on outcomes in AH and the role of infection on the onset of ACLF (...) the course of severe alcoholic hepatitis. In severe alcoholic hepatitis, acute-on-chronic liver failure is associated with high mortality and frequently occurs after an infection.Copyright © 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

2018 Journal of Hepatology

185. Early liver transplant for severe alcoholic hepatitis: establishing a new frontier by ignoring the rule? Full Text available with Trip Pro

Early liver transplant for severe alcoholic hepatitis: establishing a new frontier by ignoring the rule? 30498738 2018 12 07 2305-5839 6 20 2018 Oct Annals of translational medicine Ann Transl Med Early liver transplant for severe alcoholic hepatitis: establishing a new frontier by ignoring the rule? 411 10.21037/atm.2018.09.57 Zhu Julie J Division of Gastroenterology, University of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada. Hussaini Trana T The Faculty

2018 Annals of Translational Medicine

186. Non‐alcoholic fatty liver disease in patients with autoimmune hepatitis Full Text available with Trip Pro

Non‐alcoholic fatty liver disease in patients with autoimmune hepatitis The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing all over the world. NAFLD develops in patients with liver disease, including patients with autoimmune hepatitis (AIH). NAFLD and AIH have some similar laboratory and histological findings. The aim of this study was to elucidate the characteristics of AIH patients with NAFLD.We re-evaluated the nationwide survey performed in Japan in 2015 of AIH (...) patients diagnosed between 2009 and 2013.A total of 1151 subjects (144 men and 1007 women) were enrolled in the present study. The overall prevalence of NAFLD was 17.0%. Compared to AIH without NAFLD, AIH patients with NAFLD had the following characteristics: (i) low female-to-male ratio, (ii) older age, (iii) mild elevation in hepatobiliary enzymes, (iv) histologically progressive fibrosis and mild plasma cell infiltration or mild lobular hepatitis, (v) lower prevalence of prednisolone administration

2018 JGH Open: An Open Access Journal of Gastroenterology and Hepatology

187. Bariatric Surgery Versus Non-alcoholic Steato-hepatitis

Bariatric Surgery Versus Non-alcoholic Steato-hepatitis Bariatric Surgery Versus Non-alcoholic Steato-hepatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Bariatric Surgery Versus Non-alcoholic Steato (...) -Hepatitis. Condition or disease Intervention/treatment Phase Non Alcoholic Steatohepatitis Procedure: RYGB Procedure: SG Other: ILM Not Applicable Detailed Description: This is a Randomized Controlled multicentre Trial involving the Catholic University (Professor Geltrude Mingrone as PI and Professor Marco Raffaelli as co-PI) Research question in PICOT format (P) - Population: Adults 25 to 65 years of age and BMI ≥ 30 and ≤40 kg/m2 with histological diagnosis of NASH. (I) - Intervention: Roux-en-Y

2018 Clinical Trials

188. Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease Full Text available with Trip Pro

Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease To investigate the clinical, biochemical and imaging characteristics of adult cystic fibrosis (CF) patients with hepatic steatosis as compared to normal CF controls.We performed a retrospective review of adult CF patients in an academic outpatient setting during 2016. Baseline characteristics, genetic mutation analysis as well as laboratory values were collected. Abdominal (...) with non-alcoholic fatty liver disease. Long term prospective studies are needed to ascertain whether CF hepatic steatosis progresses to fibrosis and cirrhosis.

2018 World journal of hepatology

189. Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver disease Full Text available with Trip Pro

Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver disease To explore the relationship between collagen proportionate area (CPA) and portal hypertension-related clinical manifestations in alcoholic liver disease (ALD).Retrospective study with chart review of patients with ALD adressed to our center between January 2012 and December 2013 for a transjugular liver biopsy (TJLB) and hepatic hemodynamic study. Patients (...) , subdivided in 41 active alcohol drinkers and 20 durably abstinent patients. Nine healthy liver donors served as controls. Mean CPA in patients with ALD was 7.1%, with no difference between active drinkers and abstinent patients (P = 0.17). Using a fibrosis density cutoff of 5%, we observed a positive correlation between high fibrosis density and the hepatic venous pressure gradient (HVPG) only in active drinkers (P = 0.02). At 12-mo of follow-up, in the group of active alcohol drinkers, patients reaching

2018 World journal of hepatology

190. Intragastric Balloon in Compensated NASH(Non Alcoholic Steato Hepatitis) Cirrhotics

Intragastric Balloon in Compensated NASH(Non Alcoholic Steato Hepatitis) Cirrhotics Intragastric Balloon in Compensated NASH(Non Alcoholic Steato Hepatitis) Cirrhotics - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Intragastric Balloon in Compensated NASH(Non Alcoholic Steato Hepatitis) Cirrhotics The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03753438 Recruitment Status : Recruiting First Posted : November 27, 2018

2018 Clinical Trials

191. miR-203 Inhibits Alcohol-Induced Hepatic Steatosis by Targeting Lipin1 Full Text available with Trip Pro

miR-203 Inhibits Alcohol-Induced Hepatic Steatosis by Targeting Lipin1 Alcoholic liver disease (ALD) is a global liver disease which characterized by liver inflammation, fatty liver, alcoholic hepatitis, or liver cirrhosis. Alcohol abuse is one of the main reasons for liver disease. Alcoholic fatty liver (AFL) disease is the early stage of ALD and associated with the excessive lipids accumulation in hepatocytes as well as oxidative stress. MicroRNA-203 (miR-203) is known to suppress (...) the proliferation and metastasis of hepatocellular carcinoma, but the role in the progression of alcoholic liver disease is not clear and is warranted for further investigation. In the present study, we have found the expression of miR-203 is down-regulated in Gao-Binge alcoholic mice model and ethanol-induced AML-12 cell lines in vitro. Furthermore, over-expression of miR-203 decrease the lipids accumulation in liver and ethanol-induced AML-12 cells. Mechanistically, we identified that Lipin1 is a key

2018 Frontiers in pharmacology

192. Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis Full Text available with Trip Pro

Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis The complement system is a key component of the body's immune system. When abnormally activated, this system can induce inflammation and damage to normal tissues and participate in the development and progression of a variety of diseases. In the past, many scholars believed that alcoholic liver disease (ALD) is induced by the stress of ethanol on liver cells, including oxidative stress and dysfunction

2018 World journal of hepatology

193. Comprehensive Laboratory Analysis of Korean Acute Alcoholic Intoxication Patients Reveals the Need for a National Hepatitis B Virus Vaccination Program in Korea Full Text available with Trip Pro

Comprehensive Laboratory Analysis of Korean Acute Alcoholic Intoxication Patients Reveals the Need for a National Hepatitis B Virus Vaccination Program in Korea Acute alcoholic intoxication patients (AAIP) are a common public health problem. The aim of this study was to perform a comprehensive laboratory analysis for these patients to investigate the co-morbid medical problem.We retrospectively reviewed laboratory findings of AAIP who were transferred to the emergency department (ED) from (...) hemoglobin A1c (HbA1c) level (>7.0%). Positive rates of hepatitis B surface antigen and antiHBs antibody (anti-HBs Ab) were 3.5% (5/141) and 49.0% (68/141), respectively.Patients with AAIP who were transferred to ED had various laboratory abnormalities (anemia, thrombocytopenia, high HbA1c). They had low positive rate of anti-HBs Ab. This might be a public health problem, suggesting the need of hepatitis B virus vaccination program for AAIP. Our data suggest the need of further nationwide studies.

2018 Korean journal of family medicine

194. Correction to: Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease Full Text available with Trip Pro

Correction to: Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease [This corrects the article DOI: 10.1186/s12953-018-0131-y.].

2018 Proteome science

195. Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease Full Text available with Trip Pro

Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. However, its molecular pathogenesis is incompletely characterized and clinical biomarkers remain scarce. The aims of these experiments were to identify and characterize liver protein alterations in an animal model of early, diet-related, liver injury and to assess novel candidate biomarkers (...) biomarkers were analyzed by enzyme-linked immunosorbent assay in serum from adult NAFLD patients.Through proteomic profiling, we identified decreased expression of hepatic glyoxalase 1 (GLO1) in a murine model. GLO1 protein expression was also found altered in tissue biopsies from paediatric NAFLD patients. In vitro experiments demonstrated that, in response to lipid loading in hepatocytes, GLO1 is first hyperacetylated then ubiquitinated and degraded, leading to an increase in reactive methylglyoxal

2018 Proteome science

196. A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 21 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Able to provide written informed consent (either from patient or patient's legally acceptable representative) Male or female patients 21 years of age or older with BMI ≥ 20 to ≤ 40 kg/m2 Patients with alcoholic hepatitis defined as: History of heavy alcohol abuse: > 40 (...) A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2018 Clinical Trials

197. Time course of compromised urea synthesis in patients with alcoholic hepatitis. (Abstract)

Time course of compromised urea synthesis in patients with alcoholic hepatitis. Alcoholic hepatitis (AH) markedly decreases the urea synthesis capacity. We aimed to investigate the time course of this compromised essential liver function in patients with AH and its relation to treatment and survival.Thirty patients with AH were included in a prospective cohort study. We measured the substrate-independent urea synthesis capacity, i.e., the functional hepatic nitrogen clearance (FHNC (...) ), in the patients at study entry and again at three months (survivors/available: n = 17). Patients with severe disease (Glasgow Alcoholic Hepatitis Score ≥9, n = 17) were randomized to receive either prednisolone or pentoxifylline and were in addition examined after 14 days (n = 9).FHNC (normal range = 25-45 L/h) was markedly decreased at study entry (median = 5.6 (IQR = 3.0-9.6) L/h) and increased by three-fold in survivors at three months (15.1 (12.0-22.9) L/h; p < .001). In patients with severe AH, FHNC

2018 Scandinavian journal of gastroenterology Controlled trial quality: uncertain

198. Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis. (Abstract)

Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis. Chronic liver diseases are characterized by the expansion of ductular reaction (DR) cells and the expression of liver progenitor cell (LPC) markers. In alcoholic hepatitis (AH), the degree of DR expansion correlates with disease progression and short-term survival. However, little is known about the biological properties of DR cells, their impact on the pathogenesis of human liver disease (...) , and their contribution to tissue repair. In this study, we have evaluated the transcriptomic profile of DR cells by laser capture microdissection in patients with AH and assessed its association with disease progression. The transcriptome analysis of cytokeratin 7-positive (KRT7+ ) DR cells uncovered intrinsic gene pathways expressed in DR and genes associated with alcoholic liver disease progression. Importantly, DR presented a proinflammatory profile with expression of neutrophil recruiting C-X-C motif chemokine

2018 Hepatology

199. Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation. (Abstract)

Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Chronic liver disease has negative effects on health-related quality of life (HRQL). We analyzed data from the European non-alcoholic fatty liver disease (NAFLD) registry to assess the effects of NAFLD on HRQL.We collected data from 304 patients (mean age, 52.3±12.9 years) with histologically defined NAFLD enrolled prospectively into the European NAFLD Registry in Germany, the United (...) Kingdom, and Spain. The chronic liver disease questionnaire (CLDQ) was completed within 6 months of liver biopsy collection.The mean CLDQ overall score was 5.0±1.2, with the lowest score in the category fatigue (4.3±1.6) and the highest scores for activity (5.4±1.4). Women had significantly lower CLDQ scores than men (4.6±1.3 vs 5.3±1.1; P<.001). We found negative correlations between CLDQ scores and presence of obesity (P<.001), type 2 diabetes (P<.001), and dyslipidaemia (P<.01

2018 Clinical Gastroenterology and Hepatology

200. Efficacy of granulocyte colony-stimulating factor therapy in patients with severe alcoholic hepatitis

Efficacy of granulocyte colony-stimulating factor therapy in patients with severe alcoholic hepatitis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>